For patients navigating the complex journey of a lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) diagnosis, the road can become significantly more daunting when standard frontline treatments fail or when the disease returns. To address the critical need for guidance during these pivotal moments, the Lymphoma Research Foundation has announced an upcoming virtual symposium, "Ask the Doctor About Lymphoma: Navigating Relapsed/Refractory Disease," scheduled for Wednesday, June 17, 2026.
This two-hour, high-impact program is designed to bridge the gap between complex clinical data and the practical needs of patients, survivors, and their caregivers. By providing direct access to leading medical experts, the session aims to demystify the next steps in treatment pathways for those facing the hurdles of relapsed or refractory (R/R) disease.
Main Facts: A Vital Resource for the Lymphoma Community
The symposium serves as a cornerstone for patient advocacy and education. As the landscape of oncology shifts rapidly toward targeted therapies, immunotherapy, and clinical trials, patients often find themselves overwhelmed by the sheer volume of emerging information.
- Event Ask the Doctor About Lymphoma: Navigating Relapsed/Refractory Disease
- Date: Wednesday, June 17, 2026
- Time: 4:00 PM – 6:00 PM ET
- Format: Virtual (via Zoom)
- Target Audience: Patients, survivors, care partners, and dedicated supporters.
The program is structured to provide an accessible, comprehensive overview of the current state of lymphoma care. The core of the event centers on the "Ask the Doctor" segment, an extensive question-and-answer session where participants can engage with specialists regarding the nuanced decisions required when initial therapy does not achieve the desired long-term remission.
Chronology of Care: Understanding the R/R Path
When a patient is diagnosed with lymphoma or CLL/SLL, the standard of care usually involves a primary regimen—often chemotherapy, immunotherapy, or a combination thereof. However, for a subset of patients, the disease may prove "refractory," meaning it does not respond to the initial treatment, or "relapsed," meaning it returns after a period of improvement.
The Phases of Navigating Recurrence:
- Recognition: The first step is identifying the return of symptoms or evidence of disease progression through diagnostic imaging and laboratory tests.
- Re-evaluation: Physicians must reassess the tumor biology. Often, the disease may evolve, requiring updated biopsies to determine if the genetic profile of the lymphoma has changed.
- Treatment Planning: This is where the June 17th program provides the most value. Patients must decide between standard salvage therapies, high-dose chemotherapy followed by stem cell transplantation, or the rapidly expanding world of CAR-T cell therapy and clinical trials.
- Supportive Care: Throughout this cycle, the emotional and physical toll on patients and care partners necessitates a robust support system, which the Foundation addresses through its educational outreach.
Supporting Data: The Shifting Landscape of Hematologic Malignancies
The urgency of this program is underscored by the rapid evolution of hematologic oncology. According to the National Cancer Institute, while survival rates for various lymphomas have improved significantly over the last decade, the management of relapsed/refractory cases remains a clinical priority.
- Clinical Innovation: The shift from "one-size-fits-all" chemotherapy to precision medicine has introduced Bruton’s tyrosine kinase (BTK) inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors, and bispecific antibodies into the standard of care for R/R patients.
- Access to Trials: Clinical trials remain the gold standard for many patients with R/R disease. However, data suggests that patient enrollment in clinical trials is often hindered by a lack of awareness or understanding of trial protocols. This symposium aims to address these barriers by fostering transparency.
- Patient Empowerment: Studies consistently show that patients who are well-informed about their treatment options exhibit higher levels of treatment adherence and report a better quality of life during intensive therapy regimens.
Official Responses and Expert Perspectives
The program will feature Dr. Elizabeth Brem, a distinguished voice in the field of lymphoma research and patient care. Dr. Brem brings years of clinical experience in treating complex hematologic malignancies, focusing on the patient-physician relationship as a primary tool for successful outcomes.
"The goal is not just to relay medical information, but to empower the patient to be an active member of their care team," notes the Foundation’s outreach literature. By hosting this event virtually, the organization ensures that geography is not a barrier to receiving expert-level guidance.
The Foundation emphasizes that while the information provided is invaluable, it serves as an educational supplement. The program disclaimer is clear: Information provided during Foundation programs is for informational or educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider.
Implications: Why This Matters for the Patient Journey
The implications of attending such a program go beyond the immediate knowledge gained. For many patients, the feeling of helplessness is one of the most debilitating aspects of a relapse. By engaging with experts, patients transition from passive recipients of care to informed participants in their treatment trajectory.
Addressing the Care Partner Role
The program explicitly invites care partners to participate. The role of the caregiver is frequently underestimated, yet they are the primary observers of side effects, the coordinators of appointments, and the emotional anchors for the patient. Educating caregivers on how to navigate the "second-line" treatment landscape ensures a safer and more supportive environment at home.
Bridging the Gap in Industry Engagement
The symposium also serves as a nexus for the medical community. While the focus remains on the patient, the presence of pharmaceutical and research representatives ensures that the conversation remains grounded in the latest technological advancements. For industry professionals interested in supporting this educational mission, the Foundation provides specific pathways for sponsorship, ensuring that these programs remain free and accessible to the patient population.
How to Participate
Registration for the event is now open. The Lymphoma Research Foundation has streamlined the process to ensure accessibility:
- Online Registration: Prospective attendees can register via the official Foundation website.
- Direct Contact: For those who prefer personal assistance, the Helpline is available at 800-500-9976 or via email at [email protected].
- Virtual Access: Upon registration, participants will receive an email containing specific instructions for joining the Zoom session. The program is designed to be accessible both via internet-enabled devices and standard telephone lines, ensuring inclusivity for those with limited technological access.
Final Thoughts
Navigating a relapse is undeniably one of the most challenging chapters in a patient’s life. However, it is also a chapter defined by new possibilities in medicine. The June 17, 2026, symposium offers a lifeline—a chance to turn fear into strategy, and uncertainty into a plan. Whether you are a patient in the midst of treatment, a survivor monitoring for signs of recurrence, or a caregiver providing unwavering support, this program offers the tools necessary to face the future with clarity and confidence.
For more information on patient education programs, please refer to the official Patient Education Program Disclaimer.
